Skip to main content
Fig. 2 | BMC Dermatology

Fig. 2

From: Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial

Fig. 2

Subset analysis design. BIW: twice weekly; BSA: body surface area; DLQI: Dermatology Life Quality Index; EQ-5D: EuroQoL-5 Dimension; FACIT: Functional Activity in Chronic Therapy; HRQoL: health-related quality of life; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment of psoriasis; QW: once weekly; WPAI: Work Productivity and Activity Impairment scale

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us